146 related articles for article (PubMed ID: 18704096)
1. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
De Leonibus E; Managò F; Giordani F; Petrosino F; Lopez S; Oliverio A; Amalric M; Mele A
Neuropsychopharmacology; 2009 Feb; 34(3):729-38. PubMed ID: 18704096
[TBL] [Abstract][Full Text] [Related]
2. Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
Domenici MR; Potenza RL; Martire A; Coccurello R; Pèzzola A; Reggio R; Tebano MT; Popoli P
J Neurosci Res; 2005 Jun; 80(5):646-54. PubMed ID: 15880742
[TBL] [Abstract][Full Text] [Related]
3. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Marin C; Bonastre M; Aguilar E; Jiménez A
Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
[TBL] [Abstract][Full Text] [Related]
4. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
[TBL] [Abstract][Full Text] [Related]
5. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease.
Phillips JM; Lam HA; Ackerson LC; Maidment NT
Eur J Neurosci; 2006 Jan; 23(1):151-60. PubMed ID: 16420425
[TBL] [Abstract][Full Text] [Related]
6. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.
Chen L; Liu J; Ali U; Gui ZH; Hou C; Fan LL; Wang Y; Wang T
Brain Res Bull; 2011 Feb; 84(3):215-23. PubMed ID: 21255635
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
Yamamoto N; Soghomonian JJ
Neuroscience; 2009 Nov; 163(4):1171-80. PubMed ID: 19660528
[TBL] [Abstract][Full Text] [Related]
8. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
Breysse N; Baunez C; Spooren W; Gasparini F; Amalric M
J Neurosci; 2002 Jul; 22(13):5669-78. PubMed ID: 12097518
[TBL] [Abstract][Full Text] [Related]
9. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
10. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
Zhang JN; Huang YL; Yang HM; Wang Y; Gu L; Zhang H
Mol Cell Neurosci; 2021 Jan; 110():103572. PubMed ID: 33248235
[TBL] [Abstract][Full Text] [Related]
11. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y
Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547
[TBL] [Abstract][Full Text] [Related]
12. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
[TBL] [Abstract][Full Text] [Related]
13. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats.
Spooren WP; Gasparini F; Bergmann R; Kuhn R
Eur J Pharmacol; 2000 Oct; 406(3):403-10. PubMed ID: 11040347
[TBL] [Abstract][Full Text] [Related]
14. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
Turle-Lorenzo N; Breysse N; Baunez C; Amalric M
Psychopharmacology (Berl); 2005 Apr; 179(1):117-27. PubMed ID: 15726332
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.
Coccurello R; Breysse N; Amalric M
Neuropsychopharmacology; 2004 Aug; 29(8):1451-61. PubMed ID: 15039773
[TBL] [Abstract][Full Text] [Related]
17. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
Morin N; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
[TBL] [Abstract][Full Text] [Related]
18. Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice.
Managò F; Lopez S; Oliverio A; Amalric M; Mele A; De Leonibus E
Psychopharmacology (Berl); 2013 Apr; 226(3):541-50. PubMed ID: 23192313
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors.
Lea PM; Movsesyan VA; Faden AI
Br J Pharmacol; 2005 Jun; 145(4):527-34. PubMed ID: 15821750
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5.
Fieblinger T; Sebastianutto I; Alcacer C; Bimpisidis Z; Maslava N; Sandberg S; Engblom D; Cenci MA
J Neurosci; 2014 Mar; 34(13):4728-40. PubMed ID: 24672017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
